Overexpression of MRP4 mediated the acquired docetaxel resistance, targeting MRP4 treatment which re-sensitized docetaxel-resistant prostate cancer cells to docetaxel chemotherapy (25). Here, ABCC4 is linked to prostate carcinoma.